BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013;310:930-937. [PMID: 24002279 DOI: 10.1001/jama.2013.228052] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Mukerji R, Briles DE. New Strategy Is Needed to Prevent Pneumococcal Meningitis. Pediatr Infect Dis J 2020;39:298-304. [PMID: 32032170 DOI: 10.1097/INF.0000000000002581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, Koopmans MPG, van der Klis FRM, van Binnendijk RS. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis 2020;222:1452-61. [PMID: 32766833 DOI: 10.1093/infdis/jiaa479] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 42.0] [Reference Citation Analysis]
3 Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol 2014;5:365. [PMID: 25076945 DOI: 10.3389/fmicb.2014.00365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Pírez MC, Algorta G, Chamorro F, Romero C, Varela A, Cedres A, Giachetto G, Montano A. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay. Pediatr Infect Dis J 2014;33:753-9. [PMID: 24492286 DOI: 10.1097/INF.0000000000000294] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
5 Pobre K, Tashani M, Ridda I, Rashid H, Wong M, Booy R. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine. 2014;32:1423-1430. [PMID: 24492014 DOI: 10.1016/j.vaccine.2014.01.047] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
6 Almudevar A, Kaur R, Pichichero M. Statistical projection of post-vaccination antibody kinetics between dosing schedules. Vaccine 2019;37:4561-7. [PMID: 31262582 DOI: 10.1016/j.vaccine.2019.06.017] [Reference Citation Analysis]
7 Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clin Infect Dis 2018;67:367-74. [PMID: 29471432 DOI: 10.1093/cid/ciy129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
8 Ahmed SS, Lessa FC, Coradin H, Sánchez J, Carvalho MDG, Soda E, Peña C, Fernández J, Cedano D, Whitney CG, Feris-Iglesias J. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic. J Infect Dis 2021;224:S228-36. [PMID: 34469563 DOI: 10.1093/infdis/jiab134] [Reference Citation Analysis]
9 Catalioto RM, Valenti C, Bellucci F, Cialdai C, Altamura M, Digilio L, Pellacani AUE, Meini S. Booster immunization with a fractional dose of Prevnar 13 affects cell-mediated immune response but not humoral immunity in CD-1 mice. Heliyon 2021;7:e07314. [PMID: 34195422 DOI: 10.1016/j.heliyon.2021.e07314] [Reference Citation Analysis]
10 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr 2016; 5(3): 311-318 [PMID: 27610348 DOI: 10.5409/wjcp.v5.i3.311] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, Barnes M, Petit S, Farley M, Harrison LH, Holtzman C, Baumbach J, Bennett N, McGuire S, Thomas A, Schaffner W, Beall B, Whitney CG, Pilishvili T. Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016. Pediatrics 2020;145:e20190836. [PMID: 32054822 DOI: 10.1542/peds.2019-0836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Hamaluba M, Kandasamy R, Upreti SR, Subedi GR, Shrestha S, Bhattarai S, Gurung M, Pradhan R, Voysey M, Gurung S, Pradhan S, Thapa AK, Maharjan R, Kiran U, Kerridge SA, Hinds J, van der Klis F, Snape MD, Murdoch DR, Kelly S, Kelly DF, Adhikari N, Thorson S, Pollard AJ. Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. The Lancet Infectious Diseases 2015;15:405-14. [DOI: 10.1016/s1473-3099(15)70007-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
13 Tashani M, Badahdah AM, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Louth J, Rashid H, Borrow R, Booy R. Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM197-conjugate vaccine in adult Hajj pilgrims: A randomised controlled trial. Vaccine 2019;37:3562-7. [PMID: 31128875 DOI: 10.1016/j.vaccine.2019.05.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Boef AGC, van der Klis FRM, Berbers GAM, Buisman AM, Sanders EAM, Kemmeren JM, van der Ende A, de Melker HE, Rots NY, Knol MJ. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies. Vaccine 2018;36:400-7. [PMID: 29223483 DOI: 10.1016/j.vaccine.2017.11.070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Kandasamy R, Gurung M, Thorson S, Yu L, Galal U, Voysey M, Kelly S, Wahl B, Berbers G, Finnegan K, Ansari I, Paudel K, Murdoch DR, O'brien KL, Kelly DF, Goldblatt D, Shrestha S, Pollard AJ. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. The Lancet Infectious Diseases 2019;19:156-64. [DOI: 10.1016/s1473-3099(18)30568-1] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Mvula H, Heinsbroek E, Chihana M, Crampin AC, Kabuluzi S, Chirwa G, Mwansambo C, Costello A, Cunliffe NA, Heyderman RS, French N, Bar-Zeev N; VacSurv Consortium. Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study. PLoS One 2016;11:e0154997. [PMID: 27152612 DOI: 10.1371/journal.pone.0154997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
17 Madhi SA, Koen A, Jose L, Moreira M, van Niekerk N, Cutland C, François N, Ruiz-Guiñazú J, Yarzabal JP, Borys D, Schuerman L. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial. Expert Rev Vaccines 2017;16:641-56. [PMID: 28425818 DOI: 10.1080/14760584.2017.1321990] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Tashani M, Heron L, Wong M, Rashid H, Booy R. Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. J Travel Med 2017;24. [PMID: 28375507 DOI: 10.1093/jtm/tax006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Lewnard JA, Givon-Lavi N, Dagan R. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children. Clin Infect Dis 2020;71:e289-300. [PMID: 31784753 DOI: 10.1093/cid/ciz1164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
20 Maertens K, Burbidge P, Van Damme P, Goldblatt D, Leuridan E. Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy. Pediatr Infect Dis J 2017;36:1186-92. [PMID: 28399054 DOI: 10.1097/INF.0000000000001601] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 7.7] [Reference Citation Analysis]
21 Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, Berbers GAM, Sanders EAM, Rots NY. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis 2019;19:392-401. [PMID: 30938299 DOI: 10.1016/S1473-3099(18)30717-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 16.5] [Reference Citation Analysis]
22 van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, van Gaans-van den Brink JA, Kuipers B, Knol MJ, Berbers GA, Sanders EA, Rots NY, van Els CA. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis 2015;61:342-9. [PMID: 25838290 DOI: 10.1093/cid/civ274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
23 van den Berg JP, Westerbeek EA, van der Klis FR, Sanders EA, Berbers GA, van Elburg RM. Response on Pneumococcal Vaccine in Preterm Infants After Neutral and Acidic Oligosaccharides Supplementation. Pediatr Infect Dis J 2015;34:976-82. [PMID: 26153784 DOI: 10.1097/INF.0000000000000766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
24 Chen JJ, Yuan L, Huang Z, Shi NM, Zhao YL, Xia SL, Li GH, Li RC, Li YP, Yang SY, Xia JL. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China. BMJ Open 2016;6:e012488. [PMID: 27798013 DOI: 10.1136/bmjopen-2016-012488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hadjipanayis A, Efstathiou E, Michaelidou K, Papaevangelou V. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus. Vaccine 2018;36:5685-91. [DOI: 10.1016/j.vaccine.2018.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Munoz FM, Van Damme P, Dinleyici E, Clarke E, Kampmann B, Heath PT, Levy O, Leuridan E, Cutland C, Sobanjo-Ter Meulen A, Marchant A. The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward Integrating Maternal and Infant Immunization Programs. mSphere 2018;3:e00221-18. [PMID: 30404933 DOI: 10.1128/mSphere.00221-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Iwata S, Kawamura N, Kuroki H, Tokoeda Y, Miyazu M, Iwai A, Oishi T, Sato T, Suyama A, François N, Shafi F, Ruiz-Guiñazú J, Borys D. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study. Hum Vaccin Immunother 2015;11:826-37. [PMID: 25830489 DOI: 10.1080/21645515.2015.1012019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Klugman KP, Dagan R, Malley R, Whitney CG. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 773-815.e18. [DOI: 10.1016/b978-0-323-35761-6.00045-6] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32:4349-4355. [PMID: 24657717 DOI: 10.1016/j.vaccine.2014.03.017] [Cited by in Crossref: 118] [Cited by in F6Publishing: 123] [Article Influence: 16.9] [Reference Citation Analysis]
30 Bozio CH, Abdul-Karim A, Abenyeri J, Abubakari B, Ofosu W, Zoya J, Ouattara M, Srinivasan V, Vuong JT, Opare D, Asiedu-Bekoe F, Lessa FC. Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine. PLoS One 2018;13:e0203205. [PMID: 30192772 DOI: 10.1371/journal.pone.0203205] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
31 Takahashi Y, Ishiwada N, Hishiki H, Tanaka J, Akeda Y, Shimojo N, Oishi K, Kohno Y. IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations. J Infect Chemother 2014;20:794-8. [PMID: 25242584 DOI: 10.1016/j.jiac.2014.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 van Westen E, Knol MJ, Wijmenga-Monsuur AJ, Tcherniaeva I, Schouls LM, Sanders EAM, van Els CACM, Berbers GAM, Rots NY. Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine. Vaccines (Basel) 2018;6:E82. [PMID: 30544898 DOI: 10.3390/vaccines6040082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Urbancikova I, Prymula R, Goldblatt D, Roalfe L, Prymulova K, Kosina P. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine 2017;35:5186-93. [PMID: 28797727 DOI: 10.1016/j.vaccine.2017.07.103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
34 Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RM, Zancolli M, Goldblatt D, van Gageldonk PG, Tcherniaeva I, Berbers GA, Rots NY. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. PLoS One 2015;10:e0144739. [PMID: 26658902 DOI: 10.1371/journal.pone.0144739] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
35 Lowbridge C, McIntyre PB, Gilmour R, Chiu C, Seale H, Ferson MJ, Gilbert GL. Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare? Vaccine 2015;33:3234-41. [PMID: 25952557 DOI: 10.1016/j.vaccine.2015.04.079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
36 Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Clin Infect Dis 2017;64:175-83. [PMID: 27986682 DOI: 10.1093/cid/ciw720] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
37 Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. Vaccine 2019;37:4491-8. [PMID: 31272872 DOI: 10.1016/j.vaccine.2019.06.071] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
38 Swart EM, van Gageldonk PG, de Melker HE, van der Klis FR, Berbers GA, Mollema L. Long-Term Protection against Diphtheria in the Netherlands after 50 Years of Vaccination: Results from a Seroepidemiological Study. PLoS One 2016;11:e0148605. [PMID: 26863307 DOI: 10.1371/journal.pone.0148605] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
39 Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. Clin Infect Dis 2019;68:2135-43. [PMID: 30357326 DOI: 10.1093/cid/ciy920] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 36.0] [Reference Citation Analysis]
40 Wong MT, Lambeck AJ, van der Burg M, la Bastide-van Gemert S, Hogendorf LA, van Ravenswaaij-Arts CM, Schölvinck EH. Immune Dysfunction in Children with CHARGE Syndrome: A Cross-Sectional Study. PLoS One 2015;10:e0142350. [PMID: 26544072 DOI: 10.1371/journal.pone.0142350] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
41 Scheepers ED, van Lier A, Drijfhout IH, Berbers G, van der Maas NAT, de Melker HE, Knol MJ. Dutch national immunization schedule: compliance and associated characteristics for the primary series. Eur J Pediatr 2017;176:769-78. [PMID: 28429116 DOI: 10.1007/s00431-017-2904-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Licciardi PV, Temple B, Dai VTT, Toan NT, Uyen D, Nguyen CD, Phan TV, Bright K, Marimla RA, Balloch A, Huu TN, Mulholland K. Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial. Lancet Infect Dis 2021:S1473-3099(20)30775-1. [PMID: 34171233 DOI: 10.1016/S1473-3099(20)30775-1] [Reference Citation Analysis]
43 Mackenzie GA, Bottomley C, van Hoek AJ, Jeffries D, Ota M, Zaman SM, Greenwood B, Cutts F. Efficacy of different pneumococcal conjugate vaccine schedules against pneumonia, hospitalisation, and mortality: re-analysis of a randomised trial in the Gambia. Vaccine 2014;32:2493-500. [PMID: 24631086 DOI: 10.1016/j.vaccine.2014.02.081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
44 Weinberger R, van der Linden M, Imöhl M, von Kries R. Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule. Vaccine 2016;34:2062-5. [DOI: 10.1016/j.vaccine.2016.02.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
45 Zimmermann P, Perrett KP, Berbers G, Curtis N. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine. Arch Dis Child 2019;104:680-4. [PMID: 30796020 DOI: 10.1136/archdischild-2018-316254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tashani M, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Rashid H, Booy R. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial. Vaccine 2016;34:5929-37. [PMID: 27780630 DOI: 10.1016/j.vaccine.2016.10.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
47 Nissen TN, Birk NM, Smits G, Jeppesen DL, Stensballe LG, Netea MG, van der Klis F, Benn CS, Pryds O, Andersen A, Kjærgaard J, Thøstesen LM, Pihl GT, Hoffmann T, Kofoed P, Aaby P. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial. Vaccine 2017;35:2084-91. [DOI: 10.1016/j.vaccine.2017.02.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
48 Zimmermann P, Perrett KP, Messina NL, Donath S, Ritz N, van der Klis FRM, Curtis N. The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses. EClinicalMedicine 2019;13:21-30. [PMID: 31517260 DOI: 10.1016/j.eclinm.2019.06.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]